Oxbryta Sickle Cell Vaso-Occlusive Crisis Lawsuit
You may be eligible for compensationThe U.S. Food and Drug Administration (FDA) has determined that the risks of Sickle Cell Disease (SCD) medication Oxbryta may outweigh the benefits. Pharmaceutical manufacturer Pfizer has issued a recall of all lots of Oxbryta (voxelotor).
Two studies mandated by the FDA, have determined that taking Oxbryta may increase the risk of a serious condition known as a vaso-occlusive crisis, which can cause organ failure, stroke, or death. The FDA has stated that the benefits of Oxbryta do not appear to outweigh the risks.
Healthcare practitioners have been advised to closely monitor patients who were prescribed Oxbryta and to report serious side effects to the FDA. Patients currently taking Oxbryta should contact their healthcare provider before discontinuing the medication.
FDA Announces Oxbryta Recall
On September 26, 2024, the FDA, along with Pfizer, announced a recall of all lots of Oxbryta. The recall states that Oxbryta may cause an increased risk of vaso-occlusive crisis and death which may outweigh any benefits of the medication.
People who experienced a vaso-occlusive crisis (VOC), along with other serious adverse events or death after taking Oxbryta may be eligible for compensation.